Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer

Inclusion Criteria: * Signed written informed consent * Male or female ≥ 18 years of age * Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum * Metastatic colorectal carcinoma not suitable for curative-intent resection- Availability of tumor sample (or able and willing to provide tumor sample) for EGFR assessment * Presence of at least one lesion measurable unidimensionally by CT scan or MRI. (Target lesion(s) must not lie within an irradiated area) * Karnofsky performance status of \> 80 at study entry * Leucocytes ≥ 3.0 x 10 9/L and neutrophils ≥1.5 x 10 9/L, platelets ≥ 100 x 10 9/L, and hemoglobin ≥ 9 g/dL. * Bilirubin ≥ 1.5 x ULN * ASAT and ALAT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis are present) * Serum creatinine ≤ 1.5 x ULN Exclusion Criteria: * Brain metastasis (known or suspected) * Previous chemotherapy for metastatic disease. Prior adjuvant chemotherapy is allowed if the chemotherapy treatment free interval is \> 6 months. * Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study entry * Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol * Any investigational agent(s) within 4 weeks prior to entry * Previous exposure to EGFR-pathway targeting therapy * Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months * Acute or subacute intestinal occlusion or history of inflammatory bowel disease * Pre-existing neuropathy \> grade 1. In case of prior oxaliplatin containing adjuvant chemotherapy: pre-existing neuropathy ≥ 1. * Known grade 3 or 4 allergic reaction to any of the components of the treatment. * Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial) * Pregnancy or lactation * Inadequate contraception (male or female patients) if of childbearing or procreational potential * Known drug abuse/ alcohol abuse * Legal incapacity or limited legal capacity * Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent